A prospective surveillance of cardiovascular events in antiplatelet-treated arteriosclerosis obliterans patients in Japan.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Jun 2017
At a glance
- Drugs Sarpogrelate (Primary) ; Antiplatelets
- Indications Arteriosclerosis obliterans; Cardiovascular disorders; Embolism and thrombosis
- Focus Therapeutic Use
- Acronyms SEASON
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 12 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 11 May 2011 New trial record